Stock News•1 week ago
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff
GSK's Specialty Medicines are driving growth, but an approaching HIV patent cliff is pushing the company to accelerate its pipeline.
MarketLens
Is Big Pharma's Patent Cliff Driving a New M&A Wave
6 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
Biotech IPOs in 2026: A New Wave
4 months ago
What's Driving the Recent Wave of "Buy" Upgrades
6 months ago
Category
You may also like
Stock News•1 months ago
Pfizer: Still Cheap Valuation Meets A Looming Patent Cliff
Pfizer trades near intrinsic value with an expected 10% annual return, mostly from dividends, as a looming patent cliff and stretched balance sheet pressure growth. Management projects high single-dig...
Stock News•2 months ago
Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals
Big Pharma is spending at a pace not seen since 2019 to replace ~$300B in drugs losing patent protection, fueling biotech acquisitions.
Breaking News
View All →Featured Articles
Top Headlines
Stock News•1 hour ago
BABA 13-DAY DEADLINE ALERT: Alibaba Group Holding Limited Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 5, 2026 Lead Plaintiff Deadline
Stock News•2 hours ago
Nasdaq Scores Record As Oil Eases; Apple Tests Buy Point
Stock News•2 hours ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Alibaba Group Holding Limited of Class Action Lawsuit and Upcoming Deadlines – BABA
Stock News•2 hours ago
Meta Was the Worst AI Lab
Stock News•3 hours ago